Immunai says its “drug actuary” platform for validating and evaluating potential drug targets is intended to expand its capabilities beyond its harmonized single-cell immunology database, the Annotated Multiomic Immunological Cell Atlas (AMICA), which the company has built through proprietary technologies and more than 30 partnerships with Fortune 100 pharmaceutical companies and leading academic institutions, including Harvard, Stanford, Memorial Sloan Kettering, and Baylor College of Medicine . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge